Hypoxia inducible factor-1 in cancer immune suppression

Current Immunology Reviews

Volumn 6, Issue 3, 2010, Pages 260-271

  Duechler, Markus ^a   Wilczyński, Jacek R ^a,b  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer; Hypoxia inducible factor; Immunosuppression

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIN; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROSTAGLANDIN E2; STAT3 PROTEIN; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 77958047144     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791823853     Document Type: Article

References (126)

1. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
2. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
3. Holmquist L, Lofstedt T, Pahlman S. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. Adv Exp Med Biol 2006; 587: 179-93.
4. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27: 3889-3900.
5. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
6. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-74.
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3): 162-74.
8. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008; 15: 80-88.
9. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13(7): 828-35.
10. Mouillot G, Marcou C, Zidi I, et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007; 68: 277-85.
11. Rouas-Freiss N, Moreau P, Catherine Menier C, LeMaoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007; 17: 413-21.
12. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009; 229: 88-100.
13. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factorbeta1 and interleukin-10. Blood 2001; 98: 2992-8.
14. Gruber IV, El Yousfi S, Dürr-Störzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCR-zeta (zeta) and upregulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res 2008; 28: 779-84.
15. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996; 93: 13119-24.
16. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100: 2281-91.
17. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66: 5527-36.
18. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxiaadenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; 14: 5947-52.
19. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53: 262-74.
20. Qin FX. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol Immunol 2009; 6: 3-13.
21. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626-35.
22. Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-5.
23. Lu L, Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol 2008; 5: 401-6.
24. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-5.
25. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
26. Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323-34.
27. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69(5): 2000-9.
28. Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008; 57: 1679-83.
29. Nardin A, Abastado JP. Macrophages and cancer. Front Biosci 2008; 13: 3494-505.
30. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9.
31. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007; 117: 1147-54.
32. Norian LA, Rodriguez PC, O'Mara LA, et al. Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via LArginine Metabolism. Cancer Res 2009; 69: 3086-94.
33. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801-8.
34. Polak ME, Borthwick NJ, Gabriel FG, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007; 96: 1879-87.
35. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
36. Popov A, Schultze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 2008; 86: 145-160.
37. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13: 5243-8.
38. Donkor MK, Lahue E, Hoke TA, et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 2009; 9: 937-48.
39. Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693-701.
40. Kortylewski M and Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008; 20: 228-33.
41. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78: 1043-51.
42. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61.
43. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12: 1144-51.
44. Reimer T, Herrnring C, Koczan D, et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822-828.
45. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000; 143: 307-312.
46. Sabatino M, Kim-Schulze S, Panelli MC. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009; 27: 2645-52.
47. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR and Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-1392.
48. Brahimi-Horn MC, Pouysségur J. HIF at a glance. J Cell Sci 2009; 122: 1055-7.
49. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3, 721-732.
50. Pagé EL, Chan DA, Giaccia AJ, Levine M, Richard DE. Hypoxiainducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell. 2008; 19: 86-94.
51. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003; 17: 2115-7.
52. Gerber SA, Pober JS. IFN-alpha induces transcription of hypoxiainducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 2008; 181: 1052-62.
53. Zhou J, Fandrey J, Schümann J, Tiegs G, Brüne B. NO and TNFalpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol 2003; 284: C439-46.
54. Abdul-Hafez A, Shu R, Uhal BD. JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts. FASEB J 2009; 23: 1655-62.
55. Nishi K, Oda T, Takabuchi S. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal 2008; 10: 983-95.
56. Pedersen M, Löfstedt T, Sun J, Holmquist-Mengelbier L, Påhlman S, Rönnstrand L. Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. Biochem Biophys Res Commun 2008; 377: 98-103.
57. Muniyappa H, Song S, Mathews CK, Das KC. Reactive Oxygen Species-independent Oxidation of Thioredoxin in Hypoxia: Inactivation of ribonucleotide reductase and redox-mediated checkpoint control. J Biol Chem 2009; 284: 17069-81.
58. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer 2008; 44: 2766-73.
59. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocrine-Related Cancer 2007; 14: 233-44.
60. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002; 277: 50081-6.
61. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, Stat3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 3110-20.
62. Scharte M, Jurk K, Kehrel B, Zarbock A, Van Aken H, Singbartl K. IL-4 enhances hypoxia induced HIF-1alpha protein levels in human transformed intestinal cells. FEBS Lett 2006; 580: 6399-404.
63. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1a and HIF-2a in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-21.
64. Löfstedt T, Fredlund E, Holmquist-Mengelbier L, et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007; 6: 919-26.
65. Sica A, Allavena P, Mantovani A. Cancer related inflammation: The macrophage connection. Cancer Lett 2008; 264: 204-215.
66. Flamant L, Toffoli S, Raes M, Michiels C. Hypoxia regulates inflammatory gene expression in endothelial cells. Exp Cell Res 2009; 315: 733-47.
67. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-13.
68. Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M, Varesio L. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology 2008; 213: 733-49.
69. Byrne SN, Limón-Flores AY, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008; 180: 4648-55.
70. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-5.
71. Ricciardi A, Elia AR, Cappello P, et al. Transcriptome of hypoxic immature dendritic cells: modulation of chemokine/receptor expression. Mol Cancer Res 2008; 6: 175-85.
72. Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008; 29: 35-43.
73. Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111-9.
74. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
75. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloidderived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182: 240-9.
76. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett 2009; 123: 97-102.
77. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005; 65: 5278-83.
78. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanomaantigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumour cells. Blood 1999; 93: 1634-42.
79. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004; 53: 543-50.
80. Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008; 38: 2412-8.
81. Fox SB, Launchbury R, Bates GJ, et al. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. Prostate 2007; 67: 623-9.
82. Saito S, Shiozaki A, Sasaki Y, Nakashima A, Shima T, Ito M. Regulatory T cells and regulatory natural killer (NK) cells play important roles in feto-maternal tolerance. Semin Immunopathol 2007; 29: 115-22.
83. Sitkovsky M, Lukashev D. Regulation of immune cells by localtissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005; 5: 712-21.
84. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009; 30: 102-8.
85. Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxiainducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 2007; 14: 1853-62.
86. McDaid J, Yamashita K, Chora A, et al. Heme oxygenase-1 modulates the allo-immune response by promoting activationinduced cell death of T cells. FASEB J 2005; 19: 458-60.
87. Yamashita K, Ollinger R, McDaid J, et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J 2006; 20: 776-8.
88. El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007; 83: 145-52.
89. Choi BM, Pae HO, Jeong YR, Kim YM, Chung HT. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys Res Commun 2005; 327: 1066-71.
90. George JF, Braun A, Brusko TM, et al. Suppression by CD4+CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. Am J Pathol 2008; 173: 154-60.
91. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006; 16: 38-52.
92. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 2006; 66: 6683-91.
93. Jubb A M, Pham T Q, Hanby A M, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1a, and carbonic anhydrase IX in human tumours J Clin Pathol 2004; 57: 504-512.
94. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10.
95. Page EL, Robitaille GA, Pouyssegur, Richard DE. Induction of hypoxia-inducible factor-1α by transcriptional and translation mechanisms. J Biol Chem 2002; 277: 48403-9.
96. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond). 2004; 1: 3-15.
97. Smollich M, Wülfing P. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther 2008; 8: 1481-93.
98. Spinella F, Rosanò L, Di Castro V, et al. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res 2007; 67: 1725-34.
99. Huang SP, Wu MS, Shun CT, et al. Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 2005; 12: 229-41.
100. Zhong H, Willard M, Simons J. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer 2004; 112: 585-95.
101. Garedew A, Moncada S. Mitochondrial dysfunction and HIF1alpha stabilization in inflammation. J Cell Sci 2008; 121: 3468-75.
102. Land SC and Rae C. iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core. Am J Physiol Cell Physiol 2005; 289: C918-C933.
103. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31: 1037-51.
104. Han ZB, Ren H, Zhao H, et al. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 2008; 29: 1853-61.
105. Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L, Bernabéu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001; 276: 38527-35.
106. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-81.
107. Suzuki A, Kusakai G, Shimojo Y, et al. Involvement of transforming growth factor-beta 1 signaling in hypoxia-induced tolerance to glucose starvation. J Biol Chem 2005; 280: 31557-63.
108. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood 2003; 101: 2253-60.
109. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-60.
110. Niu G, Briggs J, Deng J, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 2008; 6: 1099-105.
111. Jung JE, Kim HS, Lee CS, et al. Stat3 inhibits the degradation of HIF-1α by pVHL-mediated Ubiquitination. Exp Mol Med 2008; 40: 479-485.
112. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007; 13: 6459-68.
113. Kimba Y, Abe T, Wu JL, et al. Mutant IkappaBalpha suppresses hypoxia-induced VEGF expression through downregulation of HIF-1alpha and COX-2 in human glioma cells. Oncol Res 2005; 15: 139-49.
114. Rius J, Guma M, Schachtrup C. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453: 807-11.
115. Scortegagna M, Cataisson C, Martin RJ, et al. HIF-1alpha regulates epithelial inflammation by cell autonomous NfkappaB activation and paracrine stromal remodeling. Blood 2008; 111: 3343-54.
116. Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res 2007; 67: 7368-77.
117. An J, Rettig MB Mechanism of von Hippel-Lindau proteinmediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005; 25: 7546-56.
118. Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 2009; [Epub ahead of print].
119. Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009; 100: 747-57.
120. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008; 2: 41-53.
121. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-62.
122. Lu Y, Liang K, Li X, Fan Z. Responses of cancer cells with wildtype or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer 2007; 6: 63-76.
123. Jung JE, Kim HS, Lee CS, et al. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 2007; 28: 1780-7.
124. Schulz S, Häussler U, Mandic R, et al. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer 2008; 122: 2360-2367.
125. Vuk-Pavlovic S. Rebuilding immunity in cancer patients. Blood Cells Mol Dis 2008; 40: 94-100.
126. Lewis C, Murdoch C. Macrophage Responses to Hypoxia. Am J Pathol 2005; 167: 627-35.